NCT02912884View on ClinicalTrials.gov

Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure

CompletedOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Polycythemia VeraThrombocythemia, Essential
Interventions
DRUG

No cytoreductive vs cytoreductive drugs

No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).

Trial Locations (2)

1205

Geneva University Hospitals, Geneva

SE19RT

Guy's Hospital, London

All Listed Sponsors
lead

Dr Yan Beauverd

OTHER

NCT02912884 - Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure | Biotech Hunter | Biotech Hunter